spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables

Merck Millipore BioMonitoring

Leading science company enters agreement to expand portfolio

  • Allows for more precise control of release kinetics
  • Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance
Darmstadt, Germany, July 12, 2016 - Merck, a leading science and technology company, has entered into an agreement with PCAS S.A. (Longjumeau, France) to expand Merck's excipients portfolio. Under the agreement, Merck will be the exclusive, global distributor of the Expansorb® line of biocompatible and biodegradable polymers.

The portfolio will include 38 polymers for sustained release of small molecule and selected peptide injectables, allowing customers to optimize and precisely control release kinetics of final drug products. The ability to better control and sustain the release of drugs allows for delivery via reduced numbers of injections with the same therapeutic efficacy, improving patient comfort and compliance.

"The pharmaceutical industry is increasingly interested in controlling the release of small molecules and selected peptides delivered via injection," said Andrew Bulpin, Head of Process Solutions at the life science business of Merck. "The addition of the Expansorb® polymers to our broad portfolio of excipients improves drug developers' ability to protect molecules with short in vivo half-lives and achieve the desired therapeutic effect while enhancing patient comfort and compliance."

Poly lactic acid (PLA) and poly lactic-co-glycolic acid (PLGA) polymers are biocompatible and biodegradable synthetic substances that have already been approved by the United States Food and Drug Administration and the European Medicines Agency with several drug products on the market and many more drug products in clinical development.

Expansorb® PLA and PLGA polymers are manufactured under cGMP conditions by PCAS and are expected to be sold under Merck's industry-leading Emprove® program once rigorous evaluations and certifications are complete. The pharmaceutical manufacturing industry relies on Emprove® products for documentation and regulatory information to facilitate risk assessment workflows and supplier qualification.

"PCAS is excited to bring our Expansorb® polymers to Merck and together offer the potential of significant value creation for pharmaceutical customers," said Didier Combis, Head of Custom Synthesis & Pharma Chemicals, PCAS. "This is an important collaboration, allowing us to broaden access to this powerful technology through Merck's global network and facilitate development of improved therapeutic solutions for patients."

Nanosphere and microsphere formulations based on PLGA polymers have been studied extensively for use in the delivery of peptides, therapeutic proteins, hormones and antibiotics. Future applications are expected to include the development of targeted drug-containing nanoparticles using site-specific ligands.
phone +49(0)6151 720
web www.merckmillipore.com
email Frankfurter Str. 250 64293 Darmstadt Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Charles River Laboratories Acquires KWS BioTest

WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 11, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
More info >>


White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

Industry Events

12th Annual Paediatric Clinical Trials

19-20 March 2018, Copthorne Tara Hotel, London, UK

SMi is pleased to present the return of their 12th annual Paediatric Clinical Trials Conference taking place on 19th – 20th March 2018, London, UK.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement